SETD5 in glioma cells conferred TRAIL resistance induction.

ABSTRACT: Glioblastoma (GBM) is the most aggressive and lethal form of primary brain tumor, often characterized by resistance to conventional therapies and a poor clinical prognosis. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) selectively induces apoptosis in cancer cells; however, TRAIL resistance remains a significant obstacle in GBM treatment. SETD5, a histone methyl transferase with emerging roles in chromatin remodeling and gene regulation, has been implicated in neurodevelopmental disorders and cancer, but remains poorly characterized in glioma biology. This study investigates the role of SETD5 in modulating TRAIL resistance and explores its potential as a therapeutic target in GBM. Publicly available datasets (TCGA, GTEx, GEPIA2, UALCAN, Gliovis, and GSCA) were used to ass

SUBMITTER: Taneja L 

PROVIDER: S-EPMC12479859 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature